Small Molecules

12 Nov 2007 ISTA Pharmaceuticals Presents Results from Two Phase III Clinical Trials of Xibrom(TM) QD (Once-daily) Formulation at the American Academy of Ophthalmology Annual Meeting
12 Nov 2007 Abbott Receives U.S. Food and Drug Administration Approval for New Lower-Strength Kaletra® (lopinavir/ritonavir) Tablet for Pediatric HIV Patients
12 Nov 2007 Allos Therapeutics Initiates Study of RH1 in Patients with Advanced Solid Tumors or non-Hodgkin's Lymphoma
11 Nov 2007 AtheroGenics Modifies ANDES Clinical Trial Discontinuing Highest Dose of AGI-1067
09 Nov 2007 CRESTOR(R) Now Indicated To Slow The Progression Of Atherosclerosis In Patients With Elevated Cholesterol
09 Nov 2007 VIVUS Initiates Pivotal Phase 3 Trial in Obese Patients and Announces Qnexa Dose
09 Nov 2007 Santhera Starts Phase IIb Clinical Trial with JP-1730 in Dyskinesia in Parkinson's Disease
09 Nov 2007 Phase 1 & 2 Data of Perifosine (KRX-0401) in Patients with Advanced Renal Cell Carcinoma Presented Today at the 25th Annual Chemotherapy Foundation Symposium
09 Nov 2007 Rigel R788 Raises Platelet Counts in Immune Thrombocytopenic Purpura (ITP) Patients in Phase 2 Study
09 Nov 2007 Pharmion's Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
08 Nov 2007 KeyNeurotek Pharmaceuticals Initiates Phase I Study With Cannabinoid Receptor-Agonist
08 Nov 2007 Dynogen’s prokinetic drug, DDP733, enters Phase 2b for irritable bowel syndrome with constipation
08 Nov 2007 CV Therapeutics' Selective Adenosine A1 Agonist Tecadenoson Shows Synergistic Effect with Ultra Low Dose Beta Blocker in Preclinical Atrial Fibrillation Model
08 Nov 2007 Merck Submits European Marketing Authorization Application for Sapropterin as a Treatment for Hyperphenylalaninemia
08 Nov 2007 Shire expands its Human Genetic Therapies pipeline through in-licensing agreement with Amicus Therapeutics
08 Nov 2007 Repligen Reports Positive Phase 2a Clinical Trial Results of RG2417 for Symptoms of Bipolar Disorder
08 Nov 2007 Synta Pharmaceuticals Initiates Phase 1 Clinical Trial of STA-9090, a Novel Hsp90 Inhibitor
08 Nov 2007 Milnacipran Demonstrated Significant Improvement in Pain and the Core Symptoms of Fibromyalgia Syndrome, Data Show
08 Nov 2007 FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML
07 Nov 2007 Initiation Of Enrollment In Pivotal Phase III Clinical Study Of Oral Laquinimod For Relapsing-Remitting Multiple Sclerosis
07 Nov 2007 SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients
07 Nov 2007 Neuren reports successful NNZ-2566 Phase 1b safety trial results
07 Nov 2007 Rifalazil trial (PROVIDENCE-1) fails to provide significant clinical benefit in patients with peripheral arterial disease
07 Nov 2007 Biovail Enters into Development Agreement
07 Nov 2007 Biovail Enters into Development Agreement

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up